Therapy-Related Myeloid Neoplasms in 39 Korean Patients: A Single Institution Experience
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Therapy-related myeloid neoplasms (t-MN) occur as late complications of cytotoxic therapy. This study reviewed clinical and cytogenetic characteristics of patients with t-MN at a single institution in Korea. Methods: The study subjects included 39 consecutive patients diagnosed with t-MN. Each subject’s clinical history of previous diseases, treatments, and laboratory data was reviewed, including cytogenetics. The primary diagnosis was hematologic malignancy in 14 patients and solid tumor in 25 patients. Results: Therapy-related acute myeloid leukemia (t-AML, 66.7%) was found to be more common than therapy-related myelodysplastic syndrome (t-MDS). Primary hematologic malignancies that were commonly implicated included mature B-cell neoplasm and acute leukemia. Breast cancer was the most common primary solid tumor. The mean time interval from cytotoxic therapy initiation to t-MN detection was 49 months. Chromosomal aberrations were observed in 35 patients, and loss of chromosome 5, 7, or both accounted for 41% of all cases. Balanced rearrangements occurred in 13 patients; these patients showed shorter latency intervals (mean, 38 months) than patients with loss of chromosome 5 or 7(mean, 61 months). Conclusions: In this study, we determined the clinical and cytogenetic characteristics of Korean patients with t-MN. Although our results were generally consistent with those of previous reports, we found that t-MN resulting from de novo leukemia was common and that t-AML was more common than t-MDS at presentation. Multi-institutional studies involving a larger number of patients and additional parameters are required to investigate the epidemiology, genetic predisposition, and survival rate of t-MN in Korea.
Abstract
Background: Therapy-related myeloid neoplasms (t-MN) occur as late complications of cytotoxic therapy. This study reviewed clinical and cytogenetic characteristics of patients with t-MN at a single institution in Korea. Methods: The study subjects included 39 consecutive patients diagnosed with t-MN. Each subject’s clinical history of previous diseases, treatments, and laboratory data was reviewed, including cytogenetics. The primary diagnosis was hematologic malignancy in 14 patients and solid tumor in 25 patients. Results: Therapy-related acute myeloid leukemia (t-AML, 66.7%) was found to be more common than therapy-related myelodysplastic syndrome (t-MDS). Primary hematologic malignancies that were commonly implicated included mature B-cell neoplasm and acute leukemia. Breast cancer was the most common primary solid tumor. The mean time interval from cytotoxic therapy initiation to t-MN detection was 49 months. Chromosomal aberrations were observed in 35 patients, and loss of chromosome 5, 7, or both accounted for 41% of all cases. Balanced rearrangements occurred in 13 patients; these patients showed shorter latency intervals (mean, 38 months) than patients with loss of chromosome 5 or 7(mean, 61 months). Conclusions: In this study, we determined the clinical and cytogenetic characteristics of Korean patients with t-MN. Although our results were generally consistent with those of previous reports, we found that t-MN resulting from de novo leukemia was common and that t-AML was more common than t-MDS at presentation. Multi-institutional studies involving a larger number of patients and additional parameters are required to investigate the epidemiology, genetic predisposition, and survival rate of t-MN in Korea.
참고문헌 (28)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed", pp.110~ (2008), IARC Press
- Michels SD, "Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases", Blood, 65, pp.1364~1372 (1985)
- Le Beau MM, "Clinical and cytogenetic correlations in 63 patients with therapy- related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7", J Clin Oncol, 4, pp.325~345 (1986)
- Smith SM, "Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series", Blood, 102, pp.43~52 (2003)
- Rowley JD, "International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report", Genes Chromosomes Cancer, 33, pp.331~345 (2002)
- Rund D, "Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients", Leukemia, 19, pp.1919~1928 (2005)
- Pedersen-Bjergaard J, "Insights into leukemogenesis from therapy-related leukemia", N Engl J Med, 352, pp.1591~1594 (2005)
- Pedersen-Bjergaard J, "Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy", Lancet, 2, pp.83~88 (1987)
- Thirman MJ, "Therapy-related myeloid leukemia", Hematol Oncol Clin North Am, 10, pp.293~320 (1996)
- Singh ZN, "Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant", Am J Clin Pathol, 127, pp.197~205 (2007)
- Mauritzson N, "Pooled analysis of clinical and cytogenetic features in treatmentrelated and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001", Leukemia, 16, pp.2366~2378 (2002)
- Pedersen-Bjergaard J, "Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia", Leukemia, 20, pp.1943~1949 (2006)
- Estey E, "Acute myeloid leukaemia", Lancet, 368, pp.1894~1907 (2006)
- Shaffer LG, "ISCN 2009: An International System of Human Cytogenetic Nomenclature" (2009), Karger
- Arana-Yi C, "Therapyrelated myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine", Leuk Res, 32, pp.1043~1048 (2008)
- Rund D, "Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment", Hematology, 9, pp.179~187 (2004)
- Hyoeun Shim, "Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor", Blood Research, 45(3), pp.177~182 (2010), 대한혈액학회
- Hur M, "Four cases of therapy- related leukemia", J Korean Med Sci, 14, pp.327~329 (1999)
- 이소영, "Inv(16)을 동반한 치료 관련성 급성골수성백혈병 1예", Annals of Laboratory Medicine, 27(1), pp.19~21 (2007), 대한진단검사의학회
- 서영익, "혈구탐식성림프조직구증의 저용량 Etoposide 치료 후 발생한 치료관련급성단구성백혈병 1예", Annals of Laboratory Medicine, 27(4), pp.244~247 (2007), 대한진단검사의학회
- Park TS, "Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia", Leukemia Research, 33(7), pp.1001~1004 (2009)
- Jung CL, "CKIT mutation in therapy-related acute myeloid leukemia with MLLT3", MLL chimeric transcript from t(9;11)(p22;q23), 2011, pp.41, 193~196
- Kim YG, "Therapy-related myelodysplastic syndrome", acute myeloid leukemia with del(7)(q22) in a patient with de novo AML, 2011, pp.41, 79~83
- 권애린, "성공적인 급성전골수구백혈병 치료 후 발생한 치료관련 골수종양 1예", Laboratory Medicine Online, 1(4), pp.227~231 (2011), 대한진단검사의학회
- Chandra P, "Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases", Am J Clin Pathol, 133, pp.686~693 (2010)
- Larson RA, "Therapy-related myeloid neoplasms", Haematologica, 94, pp.454~459 (2009)
- Schoch C, "Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML", Leukemia, 18, pp.120~125 (2004)
- Kern W, "Prognosis in therapy-related acute myeloid leukemia and impact of karyotype", J Clin Oncol, 22, pp.2510~2511 (2004)